Join the Myelodysplastic Syndrome group to help and get support from people like you.
Myelodysplastic Syndrome News
Related terms: MDS
Infection Tied to One-Fourth of Deaths With Lower-Risk Myelodysplastic Syndromes
TUESDAY, April 22, 2025 – Roughly one in 14 people with lower-risk myelodysplastic syndromes (LR-MDS) have an infection in the first year after diagnosis, according to a study published online April...
Multimodal Computational Framework Can Predict Prognosis of Myelodysplastic Syndromes
WEDNESDAY, Feb. 26, 2025 – A multimodal computational framework for patient stratification and prognosis prediction enables automatic identification of patient clusters, outperforming classical...
COVID-19 Mortality Higher for Leukemia, Myelodysplastic Syndrome Patients
THURSDAY, Nov. 21, 2024 – The risk for COVID-19 hospitalization is low in adults with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), but these individuals have a high mortality...
Overall Survival Improving for Umbilical Cord Blood Transplant
MONDAY, Oct. 7, 2024 – For umbilical cord blood transplant (UCBT), overall survival has improved over time, according to a study published in the October issue of Transplantation and Cellular...
FDA Approves Rytelo (imetelstat) for the Treatment of Adult Patients with Lower-Risk MDS with Transfusion-Dependent Anemia
FOSTER CITY, Calif.--(BUSINESS WIRE) June 6, 2024 – Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer,...
Servier Announces FDA Approval of Tibsovo (ivosidenib tablets) for the Treatment of IDH1-Mutated Relapsed or Refractory (R/R) Myelodysplastic Syndromes (MDS)
Tibsovo is the first and only approved targeted therapy for R/R MDS patients with a susceptible IDH1 mutation Fifth approved indication for Tibsovo solidifies Servier's leadership in mutant IDH...
U.S. FDA Approves Bristol Myers Squibb’s Reblozyl (luspatercept-aamt) as First-Line Treatment of Anemia in Adults with Lower-Risk Myelodysplastic Syndromes (MDS) Who May Require Transfusions
PRINCETON, N.J.--(BUSINESS WIRE) August 28, 2023-- Bristol Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) has approved Reblozyl (luspatercept-aamt) for the...
FDA Approves Inqovi (decitabine and cedazuridine) for Myelodysplastic Syndromes (MDS) including Chronic Myelomonocytic Leukemia (CMML)
Pleasanton, CA, Princeton, NJ, and Tokyo, Japan, July 7, 2020. Astex Pharmaceuticals, Inc.; Taiho Oncology, Inc.; and Otsuka Pharmaceutical Co., Ltd. today announce that the U.S. Food and Drug...
FDA Approves Five-Day Dosing Regimen for Dacogen (decitabine) for Injection, Offering a New Outpatient Dosing Option for Myelodysplastic Syndromes (MDS)
WOODCLIFF LAKE, N.J., March 11 /PRNewswire-FirstCall/ – Eisai Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved a five-day dosing regimen for Dacogen (decitabine)...